FDA Answers New Questions on Foreign Trial Sites Operating Under INDs

Publication Date26 May 2021
SubjectFDA,Waivers,Sponsors,Clinical Trials,Biologics,Guidance Update,Pharmaceutical Industry,Investigational New Drug Application (IND),Institutional Review Board (IRB)
AuthorJulie Tibbets,Elizabeth Mulkey
Law FirmGoodwin

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT